New IBS-D Drug Proposed for Schedule IV

Oops! Subscribers must be logged in to access this content.

Not A Controlled Substances’ Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the Controlled Substances Module.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson Controlled Substances Module, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Scheduling

New IBS-D Drug Proposed for Schedule IV

Ken Baumgartner

August 11, 2015 at 11:42:00 ET

The Drug Enforcement Administration has proposed Schedule IV control for eluxadoline, a newly approved drug for treatment of irritable bowel syndrome with diarrhea, known as IBS-d (80 Fed. Reg. 48044; Aug. 11, 2015). Eluxadoline is a new molecular entity with central nervous system opioid properties. It has mixed mu opioid receptor, kappa opioid receptor agonist and delta opioid r... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Controlled Substances’ Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the Controlled Substances Module.

Subscription Benefits

Start Your Free Trial

New IBS-D Drug Proposed for Schedule IV

My Research Folders

THOMPSON CONTROLLED SUBSTANCES

COMPLIANCE EXPERT

DEA RESOURCES

HELP

CONTACT